Bharat Parenterals Limited has issued a formal disclosure to BSE Limited regarding newspaper advertisements published on April 29, 2026, concerning proposed share transfers in physical form. The disclosure was made under Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Regulatory Compliance and SEBI Circular

The company published advertisements pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, which allows the opening of a special window for re-lodgement of transfer of shares in physical form. This regulatory framework enables shareholders to complete pending share transfer processes that were previously restricted.

Publication Details

The advertisements were published in two newspapers to ensure comprehensive reach:

Company Information and Certifications

Bharat Parenterals Limited operates as a WHO-GMP certified pharmaceutical company with Star Export House status. The company is headquartered at Survey No. 144-A, Jarod-Samlaya Road, Village Haripura, Taluka Savli, District Vadodara, Gujarat. The disclosure was signed by Sharmin Soni, Company Secretary and Compliance Officer (ICSI M. No: ACS-75694).

Share Transfer Process

The advertisement provides detailed information about proposed share transfers, including specific shareholder names, addresses, security numbers, and certificate details. The SEBI circular facilitates the completion of physical share transfers that may have been pending due to previous regulatory restrictions.

The company has ensured compliance with disclosure requirements by making the information available through multiple channels, including newspaper publications and its official website, thereby maintaining transparency with stakeholders and regulatory authorities.

Bharat Parenterals has disclosed that the U.S. Food and Drug Administration (FDA) conducted a surprise inspection at InnoXel Lifesciences facility, which resulted in regulatory observations that require attention.

FDA Inspection Details

The regulatory inspection yielded specific findings that the company must address:

Regulatory Classification

The FDA issued 5 Voluntary Action Indicated (VAI) observations during the inspection. VAI classification represents a moderate level of regulatory concern, indicating that deficiencies were identified that should be corrected but do not warrant immediate regulatory action. This classification falls between No Action Indicated (NAI) and Official Action Indicated (OAI) on the FDA's inspection outcome spectrum.

Next Steps

Bharat Parenterals is currently awaiting the final Establishment Inspection Report (EIR) from the U.S. FDA. The EIR will provide detailed documentation of the inspection findings and serve as the official record of the regulatory review. The company will need to address the identified observations to ensure compliance with FDA manufacturing standards and maintain its regulatory standing for U.S. market operations.